Social Media Ideas for Abbvie

<![CDATA[Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic]]>

<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

AbbVie Oncology

AbbVie Oncology Anonymous (not verified) Fri, 10/09/2026 - 07:09 field_thread_url https://cafepharma.com/boards/threads/abbvie-oncology.699564/...

HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.

A recent analyst lays out a concrete bull case, but it is not the only path to higher prices for AbbVie.

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.

Another potential blockbuster just joined AbbVie's drug portfolio.

Should You Buy AbbVie Stock Before Oct. 30?

The healthcare company will release its third-quarter numbers later this month.

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

AbbVie 'Concocted' Cancer Drug IP Claims, Biotech Firm Says

Biotech firms ProfoundBio and Genmab urged a Seattle federal judge Thursday to throw out rival AbbVie's lawsuit accusing two of its former employees of taking trade secrets on canc...

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

<![CDATA[Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targ...

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade

It would be hard for investors to replicate the company's return over the past decade.

Companies join forces to commercialize proposed biosimilar

Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company pr...

<![CDATA[Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Bio...

Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review...

<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...